[Skip to Content]
[Skip to Content Landing]
Comment & Response
July 2014

Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved

Author Affiliations
  • 1Institute of Neurology, Catholic University, Rome, Italy
JAMA Neurol. 2014;71(7):924-925. doi:10.1001/jamaneurol.2014.1135

To the Editor Cohen et al1 reported the efficacy and safety results of switching from natalizumab to fingolimod in patients with multiple sclerosis in a real-practice setting in the ENIGM (Enquête Nationale sur I’Introduction du Fingolimod en Relais au Natalizumab) study. We read the article with great interest; however, we are afraid that some of the presented results may not be conclusively supported by the analyses that were performed.

×